
Search
Filter Results
Displaying 291–300 of 705 for “retinitis clinical trial”
-
Oct 14, 2014
Changing Someone’s Life: A New Video Emphasizes the Need to Support FFB’s Mission
Allison Corona is one of 40 people with Leber congenital amaurosis who’ve benefitted from a gene therapy clinical trial.
-
Aug 3, 2020
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Mar 5, 2020
ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote
15-year-old Yannick Duwe transfixed the audience, describing how the treatment enabled him to use a computer instead of Braille, and work much easier and faster at school.
-
Feb 13, 2023
The Foundation Makes an Impact on Retinal Research
The Foundation Fighting Blindness’ long-term impact on moving the inherited retinal disease field forward towards treatments and cures.
-
May 2, 2016
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
When the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
A regularly-updated table of inherited retinal diseases and dry AMD clinical trials
-
Jun 21, 2019
Dr. Jacque Duncan, UCSF Professor of Clinical Ophthalmology, is currently working on therapies restoring vision for retinal degenerative diseases. Dr. Duncan has hope and optimism for the future that vision will be restored for those with retinal diseases, thanks in part by the Foundation’s work.
-
Sep 10, 2021
Apellis to Seek FDA Approval of its Dry AMD Drug
Known as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Apr 30, 2019
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.